Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Dactinomycin injection		For hospital use only
Daktacort cream	TA85 - Frequency of application of topical corticosteroids for atopic eczema	Mild potency
Danaparoid injection		Hospital use only
Danazol capsules		Hereditary angiodema (off label)
Danazol capsules		Hereditary angiodema (off-label). Red for patients initiated from August 2020.
Danthron		Treatment of constipation in terminally ill patients
Dapagliflozin	TA390 - Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes TA418 - Dapagliflozin in triple therapy for treating type 2 diabetes TA775 - Dapagliflozin for treating chronic kidney disease	For treating Type 2 diabetes in line with NICE
Dapagliflozin	TA597 - Dapagliflozin with insulin for treating type 1 diabetes	Specialist centres only for treating Type 1 diabetes
Daratumumab	TA510 - Daratumumab monotherapy for treating relapsed and refractory multiple myeloma TA573 - Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma TA897 - Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma TA917 - Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable	Hospital use only
Darbepoetin alfa (Aranesp)	TA323 - Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy	NHSE commissioned renal dialysis. CCG commissioned for use in cancer - NICE TA323.

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.